What is he best known for?
The fields of study he is best known for:
His main research concerns Tumor necrosis factor alpha, Cell biology, Apoptosis, Receptor and Signal transduction.
His research on Tumor necrosis factor alpha concerns the broader Immunology.
His Cell biology research integrates issues from Fas receptor, TRAF2, Death domain and FADD.
His work on Apoptosis is being expanded to include thematically relevant topics such as Cancer research.
His work carried out in the field of Receptor brings together such families of science as Secretion, Stimulation and Recombinant DNA, Fusion protein.
His study in Programmed cell death is interdisciplinary in nature, drawing from both NFKB1 and Signal transducing adaptor protein.
His most cited work include:
- Tumor necrosis factor signaling. (1836 citations)
- THE TRANSMEMBRANE FORM OF TUMOR NECROSIS FACTOR IS THE PRIME ACTIVATING LIGAND OF THE 80 KDA TUMOR NECROSIS FACTOR RECEPTOR (1112 citations)
- The Fas Signaling Pathway: More Than a Paradigm (703 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Tumor necrosis factor alpha, Cell biology, Apoptosis, Cancer research and Receptor.
His Tumor necrosis factor alpha study integrates concerns from other disciplines, such as Proinflammatory cytokine, Cytokine, Programmed cell death and Fusion protein.
He has researched Programmed cell death in several fields, including NFKB1 and Kinase.
His research in Cell biology is mostly focused on Signal transduction.
His biological study spans a wide range of topics, including Molecular biology and Cell culture.
His work carried out in the field of Receptor brings together such families of science as Recombinant DNA and Pharmacology.
He most often published in these fields:
- Tumor necrosis factor alpha (41.90%)
- Cell biology (34.39%)
- Apoptosis (32.81%)
What were the highlights of his more recent work (between 2017-2021)?
- Tumor necrosis factor alpha (41.90%)
- Cancer research (25.69%)
- Receptor (22.13%)
In recent papers he was focusing on the following fields of study:
Harald Wajant focuses on Tumor necrosis factor alpha, Cancer research, Receptor, Cell biology and Necroptosis.
His research integrates issues of Cytokine, Apoptosis, Programmed cell death, Downregulation and upregulation and Proinflammatory cytokine in his study of Tumor necrosis factor alpha.
His Cancer research study combines topics in areas such as Regulatory T cell, Cell, NF-κB and Co-stimulation.
His Receptor research incorporates elements of Antibody and Fusion protein.
His research in Cell biology is mostly concerned with Signal transduction.
His Necroptosis research integrates issues from Flip, Gene and GLI2.
Between 2017 and 2021, his most popular works were:
- Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation (82 citations)
- TNFR1 and TNFR2 in the Control of the Life and Death Balance of Macrophages. (61 citations)
- Expression of Tumor Necrosis Factor Receptor 2 Characterizes TLR9-Driven Formation of Interleukin-10-Producing B Cells. (26 citations)
In his most recent research, the most cited papers focused on:
His primary areas of investigation include Tumor necrosis factor alpha, Necroptosis, Cell biology, Receptor and Cancer research.
The study incorporates disciplines such as Cell, Programmed cell death and Bone marrow in addition to Tumor necrosis factor alpha.
His Necroptosis research is multidisciplinary, incorporating perspectives in Inflammation, Cytokine, Immunology and Arthritis.
Harald Wajant has included themes like Secretion, Stimulation and B cell in his Cell biology study.
His studies in Receptor integrate themes in fields like Proinflammatory cytokine and Antibody.
His work deals with themes such as Signal transduction and Immune system, which intersect with RIPK1.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
